To determine whether a similar mechanism was employed in cells treated with dual PI3K pathway inhibitor NVP-BEZ235, we assessed the combined impact of PI3K-mTOR inhibition (NVP-BEZ235 1 μM) and FOXO1 inhibition (FOXO1 inhibitor AS1842856 1 μM) on glycolytic gene expression in U87MG and DBTRG GBM cancer cell lines. The gene discussed is FOXO1; the disease is cancer.